Cyclo-Ergometry in the Patient With Acute Respiratory Distress Syndrome
Launched by BIOGIPUZKOA HEALTH RESEARCH INSTITUTE · Jan 25, 2024
Trial Information
Current as of March 23, 2025
Completed
Keywords
ClinConnect Summary
In March 2020 the World Health Organization declares the Coronavirus disease pandemic 2019. Intensive Care Units deal entirely with patients with pneumonia complicated by Acute Respiratory Distress Syndrome, requiring aggressive respiratory treatments with long periods of connection to mechanical ventilation, sedation and immobilization, contributing to the onset of acquired critical patient muscle weakness (IAPD).
IUCD is a frequent complication in intensive care units, with an incidence of 11-67%¹. Of multifactorial cause, immobilization or "bed-rest", the use of corticosteroids and neur...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient 18 years of age or older
- • Alert and cooperative (RASS agitation-sedation between -1 and +1).
- • Able to give informed consent (or authorize a family member) to be randomly assigned to receive the cyclo-ergometry program or conventional physiotherapy treatment.
- • With or without connection to mechanical ventilation (via orotracheal tube or tracheostomy).
- • Clinically stable (cardio-vascular, respiratory, neurological).
- • With an inspired oxygen fraction less than or equal to 0.6 and requiring minimal ventilatory support (positive end-expiratory pressure less than or equal to 10 cm H2O).
- Exclusion Criteria:
- • - Patients with pre-existing neuromuscular disease, spinal cord injury, cardiorespiratory arrest, stroke, patients with contraindications for mobility, pregnant women, advanced dementia or patients with life expectancy of less than 6 months or any situation that contraindicates the performance of cycloergometry.
About Biogipuzkoa Health Research Institute
Biogipuzkoa Health Research Institute is a leading clinical research organization dedicated to advancing medical knowledge and improving patient outcomes through innovative research initiatives. Located in the Basque Country, Spain, the institute focuses on a multidisciplinary approach, fostering collaboration among healthcare professionals, researchers, and industry partners. With a commitment to excellence in clinical trials, Biogipuzkoa aims to translate scientific discoveries into effective therapies and interventions, promoting health and wellbeing within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Donostia, Guipuzcoa, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0